Radioligand Therapy Peptide QC Checklist & Nā kikoʻī hoʻāʻo

Pane wikiwiki

A practitioner QC checklist for radioligand therapies mapping peptide purity, chelator site mapping, RCP testing, and radiolytic stability.

Pills 1: Maʻemaʻe Peptide Precursor & Kaulike Pono

Hoʻopili ʻana i ka peptide ma o Solid-Phase Peptide Synthesis (SPSS) a i ʻole ka fermentation microbial e hoʻopuka maoli i nā haumia pili pili. I nā noi radiopharmaceutical, Hiki i nā mea haumia peptide liʻiliʻi ke hoʻololi i nā kinetics radiolabeling a i ʻole e hoʻokūkū pololei me ka peptide i hoʻopaʻa ʻia no ka hoʻopaʻa ʻana i ka mea hoʻopaʻa maʻi maʻi..

Ki Takeaway: A 95% ʻAʻole manaʻo ka maʻemaʻe a pau ma kahi CoA inā ʻo ke koena 5% aia nā kaʻina holoi e hoʻopaʻa ʻole ʻia a i ʻole nā ​​counterions e hoʻopilikia i ka radiolabelling pH a me ka hoʻonohonoho ʻana..

Nā ʻano hāʻule maʻamau

  • Hoʻopau hui i nā mea haumia (n-1, n-2): ʻO nā ʻāpana kaʻina i ʻoki ʻia i hana ʻia i ka wā o ka hoʻohui ʻana (e.g., ma nā wahi loulou lōʻihi o PSMA-617 a i ʻole nā ​​kaʻina octapeptide cyclic o DOTA-TATE) kaʻana pinepine i ka hydrophobicity kokoke like me ka peptide lōʻihi, ka hui pū ʻana i ka wā maʻamau Reverse-Phase HPLC (RP-HPLC).
  • ʻO ka hoʻohuihui ʻana i ka ʻakika amino: Epimerization ma racemization-prone koena (e like me Cysteine, Tryptophan, a i ʻole Histidine) hoʻololi i ka hoʻohālikelike ʻekolu, e hōʻemi ana i ka pili o ka mea hoʻokipa a i ʻole e hōʻemi ana i ka hiki ke komo i ka chelator.
  • ʻAka Trifluoroacetic (TFA) Kūʻē Kūʻē: ʻO ke koena TFA i koe mai ka cleavage cocktails e hoʻololi i ka pH i ka wā o ka radiolabeling a hoʻoulu i ka ʻawaʻawa o ka cellular i lalo i loko o ka vitro a me ka in vivo assays.
  • Kaumaha nui vs. ʻAʻole kūlike ka ʻiʻo Peptide Pūnaewele: Loaʻa i nā pauka peptide lyophilized ka wai koena, counterions, a me nā paʻakai. ʻO ka hilinaʻi ʻana i ke kaumaha nui ma mua o ka nui o ka peptide net ka hopena i ka helu ʻana i ka hana molar i ka wā e hōʻailona ai..

Manaʻo Analytical Assays

  1. Orthogonal RP-HPLC / UHPLC Profiling: E hoʻohana i nā ʻāpana kū hoʻohui (e like me nā kolamu C18 a me Phenyl-Hexyl) i ka pH haʻahaʻa a kū ʻole e hoʻoholo i nā diastereomers a me nā kaʻina holoi holoi.
  2. Kiekie-Resolution Mass Spectrometry (LC-ESI-HRMS): E hōʻoia pololei i ka nui monoisotopic a me ka ʻaoʻao ʻaoʻao ʻaoʻao i nā haumia a hiki i 0.1% paepae wahi.
  3. Ion Chromatography (IC): E helu i nā koena counterions (TFA, acetate, chloride) e hōʻoia i ka hoʻololi counterion piha.
  4. ʻIkepili ʻAmina Amino (AAA): E ana i ka maʻiʻo peptide net e hiki ai i ka stoichiometry pololei i ka wā o ka radiolabelling reactions.

Nā Paepae Kūʻai Kūʻai

I ka hoʻokumu ʻana i nā ʻaelike maikaʻi no ka hoʻolako precursor maʻamau, hoʻokō i kēia mau pae kumu:

  • RP-HPLC Maʻemaʻe: ≥ 95.0% no ka nānā mua ʻana; ≥ 98.0% no nā pūʻulu IND-ʻae/clinical.
  • Hoʻokahi ʻO ka haumia kiʻekiʻe loa: < 0.5% wahi e RP-HPLC.
  • Koe TFA maʻiʻo: < 1.0% w/w (me ka hoʻololi acetate a i ʻole hydrochloride makemake).
  • Maʻiʻo Peptide Net: Hōʻike ʻia e AAA (maʻamau 80-90% no nā paʻakai lyophilized).

Hoʻohuihui Peptide Ke kūʻai nei i nā kaʻina pahuhopu paʻakikī—e like me PSMA-617 a i ʻole DOTA-TATE precursors—e hoʻokumu ana i nā ʻaelike maikaʻi o ka mea hoʻolako. peptide synthesis maʻamau a me QC analytical e hōʻoia i ka hoʻopaʻa ʻia ʻana o ka hoʻolaha ʻana o ka HPLC orthogonal a me nā kuʻina hoʻololi counterion ma mua o ka hoʻokuʻu ʻia ʻana.


Pills 2: Hoʻopili i ka palapala ʻāina & Hoʻopono Chelator

ʻO nā chelators bifunctional—e like me DOTA, HOʻohana, DOTAGA, a i ʻole NODA-MP-NCS—ua hoʻohui ʻia i ka iwi kuamoʻo peptide i ka wā paʻa-phase synthesis a ma o ka post-synthetic bioconjugation.. ʻO ka pololei regioselective ka mea nui: Hiki i kahi chelator i hoʻopili ʻia i kahi koena Lysine a i ʻole Cysteine ​​​​ke hoʻopau loa i ka hana olaola..

[Ka iwi kuamoʻo Peptide Target] [Mea hoʻohui ʻelua] [Macrocyclic Chelator (ENDOW/NOTE)]

Nā ʻano hāʻule maʻamau

  • ʻAʻohe ʻano Regioisomeric: ʻO ka hui pū ʻana ʻole i ka wā bioconjugation (e.g., Hoʻopili DOTA ma nā kaulahao ʻaoʻao Lysine a i ʻole nā ​​kūlana amine linker ma DOTA-TATE a me PSMA-617 kūkulu.), ka hana ʻana i nā regioisomers me nā kinetics paʻa i hoʻololi nui ʻia.
  • Over-Conjugation (Pākuʻi Nui-Chelator): ʻAʻole i hoʻopau ʻia ka pale kaulahao ʻaoʻao e hopena i ka lawe ʻana i nā peptides ʻO nā Peptides Synthetic ʻelua a ʻoi aku ka chelator moieties (ʻano di-DOTA a i ʻole tri-DOTA), e hoʻololi i ka biodistribution a me ka pharmacokinetics.
  • Hoʻohaʻahaʻa Ring Hydrolytic: Hydrolysis a i ʻole intramolecular apo-wehe ʻana o ka reactive chelator anhydrides a i ʻole nā ​​esters ikaika ma mua o ka hui ʻana., ka hana ʻana i nā derivatives paʻakikī ʻole.
  • ʻO ka ʻona ʻana metala: Hoʻohaumia ʻia e nā ion metala ʻole radioactive (e like me Fe³⁺, Zn²⁺, Cu²⁺, a i ʻole Al³⁺) mai nā reagents, mea aniani, a i ʻole nā ​​kolamu hoʻomaʻemaʻe. Noho wikiwiki nā metala i nā chelator macrocyclic, ke ālai ʻana i ka hoʻohui ʻana o ka radiometal therapeutic.

Manaʻo Analytical Assays

  1. Tandem LC-MS/MS Peptide Mapping: Hana i ka Dissociation-Induced Dissociation (CID) a i ʻole Electron Transfer Dissociation (ETD) tandem mass spectrometry e hoʻokaʻina i nā ʻiona ʻāpana peptide a me ka palapala ʻole i ke kūlana amino acid pololei o ka chelator..
  2. Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF-MS): E hōʻoia koke i ka hāʻawi ʻana i ke kaumaha molekala a hōʻoia i ka nele piha o nā ʻano multi-adduct.
  3. Iductively Coupled Plasma Mass Spectrometry (ICP-MS): Ke nānā ʻana i nā pūʻulu precursor no nā pae sub-ppm o ka hoʻokūkū metala hoʻololi ma mua o ka hoʻopaʻa inoa ʻana.

⚠️ ʻŌlelo Aʻo: Hoʻokahi hapa-i-miliona (ppm) pae hao (Fe³⁺) aiʻole Zinc (Zn²⁺) i loko o kahi pūʻulu precursor hiki ke hoʻemi i ka hua radiochemical ma mua o 40% ma muli o ka hoʻokūkū hoʻokūkū makemake ma luna o Lutetium-177 a i ʻole Actinium-225.

Nā Paepae Kūʻai Kūʻai

  • Regioselectivity: 100% ka hoʻopili kikoʻī pūnaewele i hōʻoia ʻia e ka ʻāpana MS/MS tandem.
  • Mono-Conjugated Species Maemae: > 98.0% maʻiʻo mono-chelator; ʻano di-chelator < 0.2%.
  • Unreacted Free Chelator: < 0.5% wahi.
  • Kaumaha i ka mea metala kaumaha (ʻO Fe, ʻO Zn, Cu, ʻO Pb): < 0.1 ppm kanaka, < 0.5 ppm huina pau i anaia e ICP-MS.

No nā kemika bioconjugation kūikawā, ka hoʻohana ʻana i kahi mea hoʻolaʻa kahua-specific chelator conjugation hōʻoia ka workflow i ka stoichiometry pololei a hoʻopau i nā mea hoʻohui ʻaoʻao ʻaoʻao ʻole..


Pills 3: Maemae Radiochemical (RCP) & Hoʻohui Isotope

Ke hoʻokomo ʻia ka conjugate peptide-chelator me ka radionuclide (e.g., 177LuCl₃ a i ʻole 225AcNO₃), hōʻoia i ka hoʻohui ʻana i ka isotope a me ka maʻemaʻe radiochemical (RCP) ʻo ia ke koi hoʻokuʻu mua no nā hoʻomākaukau radiopharmaceutical.

Nā ʻano hāʻule maʻamau

  • Hoʻopili ʻia ʻo Radiometal Complete: ʻAʻole paʻakikī ka loaʻa ʻana o ka radiochemical haʻahaʻa, radionuclide manuahi i ka hoʻonā, ka mea e alakaʻi ai i ka hōʻiliʻili ʻana o nā ʻōnaʻi (e.g., kaʻi ʻana i ka iwi iwi mai ka manuahi 177Lu a i ʻole nā ​​kaikamahine palaho manuahi 225Ac).
  • Hoʻokumu ʻia ʻo Radiometal Colloidal: ʻO nā radiometals e hana ana i nā colloid hydroxide insoluble ma ka pH kiʻekiʻe, ka mea e hoʻopili ai ma nā paia vial a i ʻole e hōʻiliʻili i loko o ke ake i ka wā o ka lawelawe in vivo.
  • ʻO Radio-TLC ka manaʻo nui: Ke hilinaʻi wale nei i ka Instant Thin-Layer Chromatography (Radio-ITLC) no ka hoʻokuʻu ʻana. ʻAʻole hiki i ka Radio-ITLC ke hoʻonā i nā ʻāpana radiolytic a i ʻole nā ​​​​huahana hoʻohaʻahaʻa peptide liʻiliʻi mai ka radioligand i hoʻopaʻa ʻia., alakaʻi i nā hopena hoʻomaʻemaʻe maikaʻi ʻole.

Manaʻo Analytical Assays

  1. Radio-HPLC / Radio-UHPLC me nā Radiodetectors Online: E hoʻohui i ka chromatography wai hoʻonā kiʻekiʻe me ka gamma, beta, a i ʻole ka ʻike lekiō. E like me ka kikoʻī ma ka noiʻi paʻi ʻia ma Radio-HPLC analytical protocols no ka radiopharmaceutical quality control, Pono ʻo Radio-HPLC e hoʻokaʻawale i nā huahana radiolytic cleavage mai nā conjugates radiolabeled intact.
  2. Lekiō Pūnaehana ʻElua-ITLC: E hoʻohana i ʻelua ʻōnaehana paʻa lima orthogonal (e.g., Silica gel ITLC me ka Ammonium Acetate:Methanol no ka metala manuahi, a me ka Citrate buffer no nā ʻano colloidal) ma ke ʻano he hōʻoia hōʻoia lua wikiwiki.

Nā Paepae Kūʻai Kūʻai

  • Lekiō-HPLC Radiochemical Purity: ≥ 95.0% no ka hookuu ana (≥ 98.0% i manaʻo ʻia no ka hoʻokele lapaʻau).
  • Haki Radionuclide manuahi: < 1.0% huina hana.
  • Colloidal / Māhele ʻāpana: < 1.0% huina hana.

Pills 4: Paʻa Radiolytic & Hoʻopaʻapaʻa ma hope o ka Lepili

ʻO ka alpha a me ka beta emitters e waiho i ka radiation ionizing kūloko. Hoʻopuka kēia ikehu i nā ʻano oxygen reactive (ROS)-e like me nā radical hydroxyl (•OH), hydrated electrons, a me ka oxygen singlet—e hoʻouka pololei i ka iwi kuamoʻo peptide a me nā kaulahao ʻaoʻao amino acid.

Radionuclide Palaho (177Ua olelo mai o Lu / 225Ua haʻi aku ʻo Ac) → ROS Generation → Side-Chain Oxidation (Met/Trp/His)

→ Ka ʻoki iwi kuamoʻo & Ma Vivo Dechelation

Nā ʻano hāʻule maʻamau

  • ʻO ka ʻoki iwi kuamoʻo Radiolytic: ʻO ka hoʻouka kaua ʻana e hoʻokaʻawale i nā paʻa peptide amide i loko o nā hola o ka hōʻailona ʻana, ka hana ʻana i nā ʻāpana radiolabeled ʻona.
  • ʻOxidation ʻaoʻao-Chain: Methionine thioether oxidation i sulfoxide/sulfone, a i ʻole Tryptophan pyrrole ring oxidation, ka mea e hōʻemi loa i ka pilina paʻa receptor.
  • Ma Vivo Dechelation & Transmetallation: ʻO ka pōʻino o ka hoʻoheheʻe ʻana i ke apo chelator a i ʻole ka paʻa o ka hoʻonohonoho ʻana e alakaʻi ana i ka nalowale o ka isotope i ke kaʻa ʻana. E like me ka mea i hōʻike ʻia ma nā loiloi ʻepekema ma paʻa chelator a me ka nānā ʻana i ka pilikia transmetallation, ʻO nā paʻakikī paʻa ʻole ke alakaʻi i ka momona o ka iwi ma waho o ka pahuhopu a me nā mea ʻawaʻawa.

Manaʻo Analytical Assays

  1. Ho'āʻo Paʻa Paʻa Manawa: E nānā i ka hoʻomaʻemaʻe radiochemical e Radio-HPLC i nā manawa i wehewehe ʻia ma hope o ka hoʻopaʻa inoa ʻana (t = 0, 2, 4, 24, a 48 hola) ma lalo o ka lumi wela a me nā kūlana mālama.
  2. Haʻawina Hoʻonaʻauao Radical Scavenger: E noʻonoʻo i ka maikaʻi o ka pale ʻana i nā mea hoʻopiʻi manuahi manuahi—e like me ka Ascorbic Acid, ʻAkika Gentisic, a me Ethanol—ma nā ʻano like ʻole.
  3. In Vitro Plasma Stability & Paʻa Paʻa: ʻO ka incubation i loko o ka serum kanaka ma 37 ° C a ukali ʻia e nā hoʻokūkū hoʻokūkū hoʻopaʻa radioligand e hōʻoia i ka mālama ʻana i ka pilina paʻa. (Kd).

No ke kōkua: E hana mau i ka ho'āʻo koʻikoʻi radiolytic i ka hana volumetric kiʻekiʻe (e.g., 50-100 MBq/mL) i ka wā o ka hōʻoia hōʻoia. Hiki ke hoʻohaʻahaʻa koke i kahi papa hana paʻa i nā hana diagnostic haʻahaʻa i ka nui o ka hopena therapeutic.

Nā Paepae Kūʻai Kūʻai

  • Maintenance Maemae Radiochemical: ≥ 90.0% RCP ma 24 hola hoʻopaʻa inoa; ≥ 85.0% ma 48 hola ma kahi mahana mālama ʻia.
  • Nā ʻano ʻano Peptide Oxidized: < 2.0% wahi kiʻekiʻe loa i mua o ka optimized radical scavengers.
  • Hoʻopaʻa ʻia ʻo Receptor Binding Affinity: Kd i loko o 2-fold o ka maʻamau kuhikuhi anuanu ʻole.

Hoʻomaopopo ka ʻōnaehana hoʻoponopono i ka hoʻopaʻa ʻana i ka hōʻoia analytical piha me ka European Medicines Agency alakaʻi hoʻoponopono no nā haumia peptide synthetic a me nā kikoʻī, e hōʻoia i ka paʻa o ka precursor a me nā ʻano analytical e kūlike me nā manaʻolana hoʻoponopono honua.


ʻO ka papa kuhikuhi kikoʻī kikoʻī ʻo RLT Peptide QC

Hiki ke kālailai Kūlana Kūlana Nui Manaʻo Analytical Assay Mea kūʻai / Ka palena kiko'ī hoʻokuʻu pūʻulu
Peptide Precursor Maʻemaʻe Hoʻohui pū i nā kaʻina holoi holoi, diastereomers, TFA mea make Hana ʻia ʻo Peptide Orthogonal RP-HPLC (C18 & Phenyl-Hexyl), LC-ESI-HRMS, Ion Chromatography Maʻemaʻe HPLC ≥ 95.0% (IND: ≥ 98.0%); Hoʻokahi haumia < 0.5%; TFA < 1.0%
Hoʻopili i ka palapala ʻāina Regioisomeric miscoupling, over-conjugation, chelator hydrolysis ʻO Tandem LC-MS/MS (Palapala palapala CID/ETD), MALDI-TOF-MS 100% Regioselectivity; Mono-chelator > 98.0%; Chelator hoʻokō ʻole < 0.5%
Nānā Metala ʻImi ʻO ka make ʻana o Chelator e nā ion hoʻokūkū (Fe³⁺, Zn²⁺, Cu²⁺) ICP-MS trace elemental analysis ʻO Fe, ʻO Zn, Cu < 0.1 ppm kanaka, < 0.5 ppm huina
Maemae Radiochemical (RCP) ʻAʻohe paʻakikī radiometal, ʻona isotope manuahi Lekiō-HPLC me ka gamma/beta detector, Lekiō Pūnaehana ʻElua-ITLC Radio-HPLC RCP ≥ 95.0% (Kuhikuhi: ≥ 98.0%); Radiometal manuahi < 1.0%
Paʻa Radiolytic Māhele amide i hoʻoulu ʻia e ka radiation, Met/Trp oxidation Ka manawa-papa Radio-HPLC (0–48 hola), ʻO ka hoʻomaʻamaʻa ʻana i nā mea hoʻonaninani RCP ≥ 90.0% ma 24 h hōʻailona hōʻailona; ʻAno ʻokiʻoki ʻia < 2.0%

Ka hui pū ʻana me nā Pūʻulu Hoʻomohala Peptide Kūikawā

ʻO ka manaʻo ʻana i nā pilikia loiloi i ka hoʻomaka ʻana o ka hoʻomohala ʻana e hoʻololi i ka hana radiopharmaceutical mai kahi kaʻina hoʻāʻo-a-hewa ʻole i ʻike ʻia i kahi reproducible., ʻepekema mākaukau paona.

Ke holomua nei i nā moho radiopharmaceutical mai ka loaʻa ʻana o ka pahuhopu a hiki i nā haʻawina hoʻonaʻauao IND, leveraging a specialized peptide CRO a me ka papa hana hoʻomohala e hōʻoia i ka hoʻoponopono ʻana i ke kaʻina, bioconjugation kiko'ī paena, a ua kūkulu pololei ʻia ka ʻano analytical ikaika i kāu kemika, hana hana, a me nā mana (CMC) papa hana.

MOL Changes provides end-to-end custom peptide synthesis and complex bioconjugation services within Class 100 nā wahi lumi hoʻomaʻemaʻe sterile. Supported by advanced LC-MS/MS, orthogonal HPLC, and comprehensive analytical testing, our team empowers biopharma developers to deliver ultra-pure, stably conjugated radiopharmaceutical precursors with complete analytical transparency.


Nīnau pinepine (FAQ)

No ke aha i lawa ʻole ai ka maʻemaʻe HPLC no nā radiopharmaceutical peptide precursors?

Standard HPLC measures UV absorbance at 214 nm a i ole 220 nm, which reflects peptide backbone absorbance but cannot distinguish between regioisomers or confirm exact chelator attachment sites. Eia kekahi, UV purity does not account for non-absorbing trace metal contaminants (like Fe³⁺ or Zn²⁺) or TFA counterions, both of which severely impair radiolabeling yield and cellular safety.

Pehea ka ʻokoʻa o Radio-HPLC mai Radio-ITLC i ka hoʻomaʻemaʻe radiochemical?

Radio-ITLC separates compounds based on simple migration on a strip, He mea maikaʻi loa ia no ka mākaʻikaʻi wikiwiki / hāʻule i ka radiometal manuahi. Eia naʻe, Loaʻa i ka Radio-ITLC ka hoʻonā chromatographic i koi ʻia e hoʻokaʻawale i nā peptides radiolabeled paʻa mai nā ʻāpana radiolytic degradation liʻiliʻi a i ʻole nā ​​​​mea i hoʻopaʻa ʻia.. Hoʻohana ʻo Radio-HPLC i nā kolamu chromatography wai i hui pū ʻia me nā mea ʻike uila pūnaewele e hoʻoholo a helu pono i nā ʻano mea lekiō a pau..

He aha nā radical scavengers ʻoi aku ka maikaʻi i ka pale ʻana i ka hōʻino radiolytic?

ʻakika Ascorbic, ʻakika gentisic, a ʻo ka ethanol nā mea hoʻopaʻa radiolytic i hoʻopaʻa ʻia no nā lāʻau lapaʻau radioligand. Hana lākou ma ke kinai wikiwiki ʻana i nā radical hydroxyl a me nā electrons hydrated i hana ʻia i ka radiolysis ma mua o ka hiki ʻana o kēlā mau radical me nā koena peptide koʻikoʻi. (e like me ka Methionine, Tryptophan, a me ka Histidine) a i ʻole ka iwi kuamoʻo chelator.

Pehea e mālama ʻia ai nā peptides precursor e mālama i ka paʻa chelator lōʻihi?

Hoʻohui ʻia ka peptide-chelator (e like me DOTA-TATE a i ʻole PSMA-617 precursors) Pono e mālama i ka lyophilized e like me nā aliquots sterile ma lalo o ke kinoea inert (argon a i ʻole nitrogen) ma -20°C a i -80°C. ʻO ka pale ʻana i nā pōʻai maloʻo maloʻo a me ka pale ʻana i ka precursor mai ka makū o ka lewa e pale i ka hydrolytic degradation o macrocyclic chelators a me ka hoʻokaʻina ʻaoʻao-chain ma mua o ka radiolabeling..

Bingyan Gao

Bingyan Gao

Mea Hana Pono a me Analytical Kaʻike kumu: ʻO ka hoʻokaʻawale ʻana a me ka ʻike ʻana i nā ʻano haumia, Hoʻomohala ʻano hana HPLC/MS, ka hoʻomaʻemaʻe kiral, a me ka hoʻokō ʻana i nā pharmacopoeias honua.

Pilikino: ʻO Bingyan Gao ka "puka kiaʻi hope" o ka maʻemaʻe peptide a me ka maikaʻi. Maikaʻi ʻo ia i ka hoʻohana ʻana i nā mea analytical kiʻekiʻe kiʻekiʻe a loea i ka hoʻomohala ʻana i nā ʻano hoʻokaʻawale chromatographic maʻamau no nā peptides hoʻololi paʻakikī.. Ua hoʻokumu ʻo ia i kahi ʻōnaehana hoʻomaʻemaʻe pono ʻole e hōʻoia i ka maʻemaʻe o ka huahana 99% a i ʻole kiʻekiʻe aʻe akā ʻike pono a hoʻopau i nā ʻano haumia i hiki ke hoʻoulu i ka immunogenicity. Me ka hoʻomaopopo hohonu ʻana i nā koi hoʻoponopono FDA a me EMA no nā lāʻau peptide, hōʻoia ʻo ia ʻo kēlā me kēia pūʻulu i hoʻokuʻu ʻia mai ka hale hana e hele pū ʻia me kahi palapala hōʻoia o ka ʻike ʻana (COA).

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana